VivoSeq
Other

Cell Therapy

0

Pipeline Programs↗

21

Active Trials↗

4

Companies Involved↗

Cell Therapy is an early-stage landscape with 0 programs across 4 companies. The most active players are TCRCure Biopharma Ltd., Northern Therapeutics, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TCRCure Biopharma Ltd.

0 programs

PreclinicalN

Northern Therapeutics

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalE

Eureka Therapeutics Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

51

clinical trials

Recruiting16 · 31%
Completed12 · 24%
Unknown status10 · 20%
Withdrawn4 · 8%
Terminated4 · 8%
Not yet recruiting3 · 6%
Other2 · 4%

Clinical Trials

Trial Activity

51 trials

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
Recruiting·TTCRCure Biopharma Ltd.·Phase 1·NCT07246304·24 enrolled
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06285825·32 enrolled
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Recruiting·LLyell Immunopharma, Inc.·Phase 3·NCT07188558·400 enrolled
DC/NK Cell Therapy
Recruiting·NNational Taiwan University Clinical Trial Center·Phase 2·NCT07202611·10 enrolled
T-cell Therapy in Patients With PML
Recruiting·HHannover Medical School·Phase 2·NCT06990087·23 enrolled
CAR T-cell Therapy in Patients With Renal Dysfunction
Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT05909059·20 enrolled
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05464719·30 enrolled
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06733610·15 enrolled
Personalized NK Cell Therapy in CBT
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02727803·100 enrolled
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT05950802·40 enrolled
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT06357754·50 enrolled
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Recruiting·JJennifer Crombie, MD·Phase 2·NCT05934448·35 enrolled
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Recruiting·CCytoAgents, Inc.·Phase 1/2·NCT05905328·54 enrolled
cfMSC Stem Cell Therapy Targeting COPD
Recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1/2·NCT07477600·30 enrolled
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Recruiting·EEureka Therapeutics Inc.·Phase 1/2·NCT04864054·20 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)